IP Verse

Ipsen competitive analysis

Latest publications and patents of Ipsen New

Explore the latest publications and patents granted to Ipsen, showcasing their recent innovations and technological advancements.

Last updated on: Sep 23, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Ipsen

EP3796929
Sep 18, 2024Suppression Of Bone Cancer-Induced AllodyniaGranted And Under Opposition
EP3758611
Jul 24, 2024Use Of Ultrasound To Guide Injection Of Non-Cytotoxic ProteaseGranted And Under Opposition
EP3266456
May 5, 2021Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic CancerGranted And Under Opposition
EP3337467
Dec 9, 2020Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer TreatmentRevoked
EP3337478
Aug 12, 2020Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And OxaliplatinGranted And Under Opposition
EP2664343
Dec 18, 2019Suppression Of CancerPatent Maintained As Amended
EP2939688
Feb 20, 2019Pharmaceutical Compositions Comprising Botulinum NeurotoxinOpposition Rejected
EP2794634
Jan 24, 2018Process For The Synthesis Of Therapeutic PeptidesNo Opposition Filed Within Time Limit
EP2548568
Jan 10, 2018Melanocortin Receptor LigandsNo Opposition Filed Within Time Limit
EP2914280
Jan 3, 2018Somatostatin-Dopamine Chimeric AnalogsNo Opposition Filed Within Time Limit

Latest oppositions filed by Ipsen

Explore patent oppositions filed by Ipsen against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 25, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4161562
High Dose And Low Volume Botulinum Toxin Treatment Of Facial WrinklesMERZ PHARMAAug 20, 2025
EP3368071
Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic EffectREVANCE THERAPEUTICSOct 26, 2022
EP3432916
Stabilized Non-Protein Clostridial Toxin CompositionsALLERGANMay 12, 2020
EP3436054
Stabilized Non-Protein Clostridial Toxin CompositionsALLERGANMay 12, 2020
EP3094331
Combination-Based Treatment MethodNEKTAR THERAPEUTICSSep 27, 2018
EP2692350
Lyophilized Preparation Of Botulinum ToxinMEDY TOXFeb 2, 2018

Latest patents of Ipsen opposed by its competitors

Explore Ipsen's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3796929
Sep 18, 2024Suppression Of Bone Cancer-Induced Allodynia1
EP3758611
Jul 24, 2024Use Of Ultrasound To Guide Injection Of Non-Cytotoxic Protease1
EP3266456
May 5, 2021Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic Cancer3
EP3337467
Dec 9, 2020Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer Treatment1
EP3337478
Aug 12, 2020Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And Oxaliplatin2
EP2664343
Dec 18, 2019Suppression Of Cancer1
EP2939688
Feb 20, 2019Pharmaceutical Compositions Comprising Botulinum Neurotoxin1
EP2957278
May 17, 2017A Stable Composition Comprising Pthrp And Uses Thereof2
EP2677029
May 10, 2017Methods For The Manufacture Of Proteolytically Processed Polypeptides1
EP2861210
May 3, 2017Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan1

Latest PTAB cases involving Ipsen

Discover the latest PTAB cases involving Ipsen, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 29, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Ipsen

IPR2025-00505Jan 17, 2025CSPC PHARMACEUTICAL GROUPIPSEN BIOPHARMTrial Instituted

Peer Comparison New

IP litigation analysis comparing Ipsen with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
IPSEN - 1 - - Non-Active
IVA SCHMETZ1 - - - Highly Aggressive